MedTrace Logo

Rocklatan Retinal Perfusion OCT Study

NCT07174401 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-12-24

No results posted yet for this study

Summary

The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.

Conditions

Interventions

DRUG

Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.

The eye not selected as the study eye will be used for comparison so both eyes will be imaged with the study devices to assess blood flow changes.

DEVICE

Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.

One OCT device is FDA-cleared while the other is still experimental. Both devices assess blood flow in different ways.

Sponsors & Collaborators

  • Alcon Research

    collaborator INDUSTRY

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • David Huang, MD, PhD · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-12-31
Completion
2027-10-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07174401 on ClinicalTrials.gov